Scientists Have Submitted A New Drug To Treat HIV

Scientists Have Submitted A New Drug To Treat HIV.
Scientists are reporting cock's-crow but cheering results from a changed drug that blocks HIV as it attempts to invade humanitarian cells. The approach differs from most au courant antiretroviral therapy, which tries to limit the virus only after it has gained player to cells penile enlargement surgery in the auburn. The medication, called VIR-576 for now, is still in the prematurely phases of development.

But researchers say that if it is successful, it might also circumvent the medicine resistance that can undermine standard therapy, according to a report published Dec 22 2010 in Science Translational Medicine. The fresh near is an attractive one for a number of reasons, said Dr Michael Horberg, manager of HIV/AIDS for Kaiser Permanente in Santa Clara, California. "Theoretically it should have fewer party paraphernalia and indeed had minimal adverse events in this study and there's indubitably less of a chance of mutation in developing resistance to medication," said Horberg, who was not confused in the study.

Viruses replicate inside cells and scientists have fancy known that this is when they tend to mutate - potentially developing untrodden ways to resist drugs. "It's for the most part accepted that it's harder for a virus to mutate largest cell walls".

The new drug focuses on HIV at this pre-invasion stage. "VIR-576 targets a go of the virus that is different from that targeted by all other HIV-1 inhibitors," explained chew over co-author Frank Kirchhoff, a professor at the Institute of Molecular Virology, University Hospital of Ulm in Ulm, Germany, who, along with several other researchers, holds a conspicuous on the inexperienced medication. The end is the gp41 fusion peptide of HIV, the "sticky" end of the virus's outer membrane, which "shoots as if a 'harpoon'" into the body's cells, the authors said.